Summary
2.20 0.05(2.33%)05/16/2024
Pacific Biosciences of California Inc (PACB)
Pacific Biosciences of California Inc (PACB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -6.06 | 12.73 | -45.93 | -70.57 | -72.97 | -84.82 | -74.69 | -88.69 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.86 | |
| Open | 2.01 | |
| High | 2.04 | |
| Low | 1.82 | |
| Volume | 9,650,411 | |
| Change | -0.12 | |
| Change % | -6.06 | |
| Avg Volume (20 Days) | 12,722,354 | |
| Volume/Avg Volume (20 Days) Ratio | 0.76 | |
| 52 Week Range | 1.25 - 14.55 | |
| Price vs 52 Week High | -87.22% | |
| Price vs 52 Week Low | 48.80% | |
| Range | -7.46 | |
| Gap Up/Down | -0.17 | |
Fundamentals | ||
| Market Capitalization (Mln) | 586 | |
| EBIDTA | -282,536,992 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1700 | |
| WallStreet Target Price | 6.00 | |
| Book Value | 2.3840 | |
| Earnings Per Share | -1.1400 | |
| EPS Estimate Current Quarter | -0.2800 | |
| EPS Estimate Next Quarter | -0.2700 | |
| EPS Estimate Current Year | -1.0100 | |
| EPS Estimate Next Year | -0.8200 | |
| Diluted EPS (TTM) | -1.1400 | |
| Revenues | ||
| Profit Marging | -1.4813 | |
| Operating Marging (TTM) | -2.0982 | |
| Return on asset (TTM) | -0.1084 | |
| Return on equity (TTM) | -0.4428 | |
| Revenue TTM | 200,431,008 | |
| Revenue per share TTM | 0.7690 | |
| Quarterly Revenue Growth (YOY) | -0.0020 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 53,473,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.2112 | |
| Revenue Enterprise Value | 5.7446 | |
| EBITDA Enterprise Value | -4.1543 | |
| Shares | ||
| Shares Outstanding | 272,356,000 | |
| Shares Float | 270,836,146 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.22 | |
| Insider (%) | 1.85 | |
| Institutions (%) | 101.44 | |
05/15 09:45 EST - prnewswire.com
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif.
Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif.
05/10 12:21 EST - zacks.com
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.
05/09 21:49 EST - seekingalpha.com
Pacific Biosciences of California, Inc. (PACB) Q1 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp. Daniel Brennan - TD Cowen Doug Schenkel - Wolfe Research Sung Ji Nam - Scotiabank Tejas Savant - Morgan Stanley Operator Hello and welcome to the PacBio First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Pacific Biosciences of California, Inc. (PACB) Q1 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp. Daniel Brennan - TD Cowen Doug Schenkel - Wolfe Research Sung Ji Nam - Scotiabank Tejas Savant - Morgan Stanley Operator Hello and welcome to the PacBio First Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
05/09 19:31 EST - zacks.com
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/09 19:11 EST - zacks.com
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago.
05/09 16:05 EST - prnewswire.com
PacBio Announces First Quarter 2024 Financial Results
MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.
PacBio Announces First Quarter 2024 Financial Results
MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.
05/07 13:16 EST - zacks.com
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
05/02 10:01 EST - zacks.com
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know
Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know
Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
04/25 10:36 EST - zacks.com
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
04/23 13:00 EST - zacks.com
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
04/17 14:01 EST - zacks.com
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.
04/16 14:47 EST - investorplace.com
The Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's Leaving
At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors.
The Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's Leaving
At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors.
04/16 08:05 EST - prnewswire.com
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.
04/03 11:56 EST - zacks.com
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
03/27 08:00 EST - prnewswire.com
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data.
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data.
03/22 16:30 EST - prnewswire.com
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on March 18, 2024.
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on March 18, 2024.
03/19 12:42 EST - seekingalpha.com
Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
PacBio expands product adoption, introducing Revio and Onso, enhancing market and technological reach. Despite 10% growth since 2015, dilution eroded shareholder value; pivot possible with 25% growth through 2029 and improved financing mix. Stand-alone and peer analyses show optimism despite further dilution risks, with brokers forecasting a 178% upside.
Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
PacBio expands product adoption, introducing Revio and Onso, enhancing market and technological reach. Despite 10% growth since 2015, dilution eroded shareholder value; pivot possible with 25% growth through 2029 and improved financing mix. Stand-alone and peer analyses show optimism despite further dilution risks, with brokers forecasting a 178% upside.
03/19 08:08 EST - benzinga.com
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
03/13 11:21 EST - zacks.com
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
03/12 09:05 EST - prnewswire.com
PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions.
PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions.